Testosterone Levels and Survival in Advanced Prostate Cancer Patients on Triptorelin

What is it about?

The study aimed to evaluate the association between low nadir testosterone during treatment with triptorelin pamoate, a luteinizing hormone-releasing hormone (LHRH) agonist, and improved clinical outcomes in patients with advanced prostate cancer. The study used a retrospective analysis of clinical trial data from three Phase III studies of triptorelin monotherapy. The sample size comprised 592 patients, with most receiving triptorelin monotherapy. The study found that better overall survival (OS) and disease-specific survival (DSS) were observed with decreasing levels of nadir testosterone. The lowest survival rates were observed in the group with testosterone between 0.35 and 0.7 nmol/L. The findings suggest that low testosterone levels achieved during treatment with triptorelin are associated with improved OS and DSS in patients with advanced prostate cancer. [Some of the content on this page has been created by AI]

Featured Image

Why is it important?

The study is important because it evaluates whether low nadir testosterone during treatment with the LHRH agonist triptorelin pamoate is associated with improved clinical outcomes in patients with advanced prostate cancer. The findings have important implications for the management of patients with advanced prostate cancer, as they suggest that achieving lower testosterone levels during treatment may improve overall and disease-specific survival. Key Takeaways: 1. The study is a retrospective analysis of clinical trial data from three prospective Phase III studies of triptorelin monotherapy in patients with advanced prostate cancer. 2. The sample size comprised 592 patients, with most receiving triptorelin monotherapy; four reported concomitant androgen receptor-axis-targeted therapy. 3. Nadir testosterones of <0.35, ≥0.35 to <0.7, ≥0.7 to <1.7 and ≥1.7 nmol/L were achieved by 96%, 3.2%, 0.34% and 0.17% of patients, respectively. 4. Better overall survival (OS) with decreasing level of nadir testosterone was observed, and this persisted after sensitivity/supplemental analyses. 5. Differences in disease-specific survival (DSS) with decreasing levels of nadir testosterone were not statistically significant in the primary analysis, but were in sensitivity/supplemental analyses.